SCHEMBL10323153

SCHEMBL10323153

NC1CCC(Nc2ncc3c(-c4ccnc(NCc5ccccc5)n4)n[nH]c3n2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 2/20 0.52
▸ MAPK9 P45984 2/20 0.52
▸ MAPK10 P53779 1/20 0.52
▸ CCNT1 O60563 3/20 0.49
▸ CDK1 P06493 5/20 0.47
▸ CCNB1 P14635 4/20 0.47
▸ CCNB2 O95067 3/20 0.47
▸ CCNB3 Q8WWL7 3/20 0.47
▸ FLT3 P36888 3/20 0.47
▸ MAPKAPK2 P49137 2/20 0.47
▸ CSNK2A1 P68400 2/20 0.47
▸ CDC7 O00311 1/20 0.47
▸ CHEK1 O14757 1/20 0.47
▸ DCLK1 O15075 1/20 0.47
▸ MAPK13 O15264 1/20 0.47
▸ PDPK1 O15530 1/20 0.47
▸ DAPK3 O43293 1/20 0.47
▸ DYRK3 O43781 1/20 0.47
▸ JAK2 O60674 1/20 0.47
▸ PRKD3 O94806 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10353744 1.00 MAPK8 (0.52) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10353597 0.91 CCNT1 (0.50) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10323804 0.91 CCNT1 (0.50) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10323485 0.89 CCNT1 (0.51) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10322963 0.89 CCNT1 (0.60) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10353070 0.89 CCNT1 (0.60) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10353673 0.89 CCNT1 (0.51) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10353168 0.89 CCNT1 (0.51) MAPK8MAPK9MAPK10CCNT1CDK1
SCHEMBL10323542 0.88 CCNT1 (0.62) CCNT1CDK1CCNB1FLT3PIM1
SCHEMBL10353321 0.88 CCNT1 (0.62) CCNT1CDK1CCNB1FLT3PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US claimed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US claimed
US-8362023-B2 Pyrazolo pyrimidines HOFFMANN-LA ROCHE INC. (US) 2013-01-29 — — US disclosed
WO-2012098068-A1 PYRAZOLO PYRIMIDINES AS DYRK1A AND DYRK1B INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 — — WO disclosed
US-20120184508-A1 PYRAZOLO PYRIMIDINES BIODURO (BEIJING) COMPANY LTD. (CN) 2012-07-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184508-A1 PYRAZOLO PYRIMIDINES TYMS, TYMP, TP53 MAPK8 1678/4885MAPK9 1108/4885MAPK10 1730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback